Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
Full article >>
Tuesday, April 14, 2009
Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment